Roche Holding Ag

• 

  Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab

  Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.

• 

  China Approves Roche Arthritis Drug To Treat Some Coronavirus Patients

  China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover.

• 

  Study Finds Targeted Cancer Drugs May Work In Range Of Tumor Types

  Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected.

• Big Pharma pushes for US action against India over patent worries: report

  Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

• Novartis offers $5-billion share buyback to investors

  Swiss drug maker Novartis AG has offered investors a $5-billion sweetener through a share buyback programme, signalling a sharper focus on shareholder rewards as it moves away from the big takeovers of the past.

• Roche cancer drug suffers patent setback in India

  India has partly revoked patents granted to a Roche Holding AG breast cancer medicine, the Swiss firm said on Sunday, in the latest regulatory setback for western drug makers trying to crack the fast-growing market.

• Top generic drugmakers look to US as patents end

  India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this year in the lucrative U.S. market.

• Indian drugs will now face backlash, warn analysts in US after Novartis ruling

  While India celebrates the Novartis ruling, the United States is condemning it. The US provides nearly 50 per cent of the profits to big pharma and India's bold decision has sent alarm waves in the lobbyist circles.

• Big Pharma down, not out, after Novartis patent blow

  Stung by a landmark patent defeat, Western drug-makers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world's eighth largest market for medicines by 2016.

• Novartis judgement: What it means for you

  The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.

• Pharma giant Novartis waits nervously on Glivec drug patent verdict today

  Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country.

• Pfizer to appeal India decision to revoke cancer drug patent

  Pfizer Ltd, the India unit of U.S. drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug Sutent. The company, which will appeal before the Intellectual Property Appellate Board, said on Friday the Indian Patent Office's decision raised concerns over India's commitment to protect intellectual prop...

• India court rules for Cipla against roche in patent case

  An Indian court has ruled in favour of local drugmaker Cipla in a patent infringement case filed by Switzerland's Roche Holding AG over Cipla's cancer drug Erlocip, a senior executive of the Indian company said.

• Roche to launch cheaper cancer drugs in India

  The Swiss firm has tied up with Emcure Pharmaceuticals Ltd to launch local brands of its Herceptin and Mabthera cancer drugs.